Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptorum Group Limited stock logo
APM
Aptorum Group
$4.56
-0.4%
$5.36
$1.35
$17.49
$23.62M1.411.32 million shs14,066 shs
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
$1.99
-16.7%
$2.91
$1.87
$8.35
$15.62M0.391.45 million shs361,815 shs
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
$1.99
-2.0%
$2.09
$1.90
$9.25
$21.77M0.6321,492 shs5,902 shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.91
-4.0%
$2.03
$1.84
$4.35
$22.02M1.0318,463 shs10,358 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptorum Group Limited stock logo
APM
Aptorum Group
+1.33%+1.78%-3.58%-52.44%+62.41%
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
-4.40%-11.48%-16.14%-35.05%-41.28%
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
+9.47%+4.02%-1.89%-16.80%-27.78%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-1.97%-4.33%-10.36%-13.10%-48.31%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/AN/AN/AN/AN/A
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
N/AN/AN/AN/AN/AN/AN/AN/A
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
1.4 of 5 stars
3.54.00.00.02.10.00.0
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/A
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
N/AN/AN/AN/A
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
3.00
Buy$5.00151.26% Upside
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.00
HoldN/AN/A

Current Analyst Ratings

Latest TXMD, APM, BFRG, and GDTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2024
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$5.00 ➝ $5.00
(Data available from 6/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptorum Group Limited stock logo
APM
Aptorum Group
$430K54.93N/AN/A$2.97 per share1.54
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
$60K260.36N/AN/A$0.43 per share4.63
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
N/AN/AN/AN/A$0.78 per shareN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.30M16.94N/AN/A$2.77 per share0.69

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptorum Group Limited stock logo
APM
Aptorum Group
-$2.83MN/A0.00N/AN/AN/AN/A7/30/2024 (Estimated)
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
-$5.36M-$0.88N/AN/AN/A-131.39%-114.76%8/12/2024 (Estimated)
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
-$3.13MN/A0.00N/AN/AN/AN/A7/22/2024 (Estimated)
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$10.28MN/A0.00N/AN/A-21.15%-13.08%8/12/2024 (Estimated)

Latest TXMD, APM, BFRG, and GDTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/10/2024Q1 2024
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
N/A-$0.26-$0.26-$0.26N/AN/A
5/10/2024Q1 2024
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A-$0.07-$0.07-$0.08N/A$0.31 million
3/29/2024Q4 2023
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
N/A-$0.17-$0.17-$0.17N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/AN/A
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
N/AN/AN/AN/AN/A
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptorum Group Limited stock logo
APM
Aptorum Group
0.20
1.18
1.18
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
N/A
9.05
9.04
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
0.04
14.09
14.09
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
1.78
1.78

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aptorum Group Limited stock logo
APM
Aptorum Group
3.80%
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
0.96%
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
0.04%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%

Insider Ownership

CompanyInsider Ownership
Aptorum Group Limited stock logo
APM
Aptorum Group
63.99%
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
N/A
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
N/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aptorum Group Limited stock logo
APM
Aptorum Group
35.18 million1.87 millionNot Optionable
Bullfrog AI Holdings, Inc. stock logo
BFRG
Bullfrog AI
47.85 millionN/ANot Optionable
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
N/A10.94 millionN/ANot Optionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
111.53 million11.39 millionOptionable

TXMD, APM, BFRG, and GDTC Headlines

Recent News About These Companies

TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com
TherapeuticsMD Inc TXMD
TherapeuticsMD to Consider Strategic Alternatives

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptorum Group logo

Aptorum Group

NASDAQ:APM
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.
Bullfrog AI logo

Bullfrog AI

NASDAQ:BFRG
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
CytoMed Therapeutics logo

CytoMed Therapeutics

NASDAQ:GDTC
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. It has research collaboration agreement with Sengkang General Hospital Pte Ltd to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (UC-MSCs) to treat cartilage injury. The company was incorporated in 2018 and is headquartered in Singapore.
TherapeuticsMD logo

TherapeuticsMD

NASDAQ:TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.